Klin Farmakol Farm. 2025;39(1):57-61 | DOI: 10.36290/far.2025.020

The use of therapeutic second-generation antipsychotics level monitoring in the individualization of schizophrenia pharmacotherapy

Anna Králová1, 2, Petr Potměšil2, Miloslav Kopeček3, 4
1 Oddělení klinické farmacie Fakultní nemocnice Královské Vinohrady, Praha
2 Ústav farmakologie, 3. lékařská fakulta, Univerzita Karlova, Praha
3 Klinika psychiatrie a lékařské psychologie 3. lékařská fakulta, Univerzita Karlova, Praha
4 Národní ústav duševního zdraví, Klecany

Therapy for schizophrenia involves a complex treatment plan consisting of social interventions, psychotherapy, and pharmacotherapy. Second-generation antipsychotics are the cornerstone of the treatment due to their pharmacological profile and lower incidence of side effects. Antipsychotika treatment is long-term and extends beyond the acute phase. Maintenance therapy is crucial to prevent relapse. Determining the plasmatic levels of antipsychotic drugs, known as therapeutic drug monitoring, helps adjust the dose for each patient individually. This process also helps minimize toxicity, monitor adherence, and reduce treatment costs.

Keywords: schizophrenia, atypical antipsychotics, therapeutic drug monitoring.

Accepted: April 15, 2025; Published: April 29, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Králová A, Potměšil P, Kopeček M. The use of therapeutic second-generation antipsychotics level monitoring in the individualization of schizophrenia pharmacotherapy. Klin Farmakol Farm. 2025;39(1):57-61. doi: 10.36290/far.2025.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Steimer W. Pharmacogenetic and psychoactive drug therapy: Ready for the patient? Ther Drug Monit. 2010;32:381-386. Go to original source... Go to PubMed...
    2. Libiger J. Schizofrenní poruchy. In: Hösch C, Libiger J, Švestka ( Eds). Psychiatrie, druhé doplněné a přepracované vydání. Praha: Tigris. 2004: 883. ISBN 8090013074.
    3. Mohr P, et al. Klinická psychofarmakologie. 2. rozšířené vydání. Maxdorf 2025. ISBN 978-80-7345-817-1.
    4. Uschida H, Takeuchi H, Graff-Guerrero A, et al. Dopamine D2 Receptor Occupancy and Clinical Effects. J Clin Psychopharmacol. 2011;31(4):497-592. doi:10.1097/JCP.0b013e318221aad. Go to original source...
    5. Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011; 17(2):97-103. doi:10.1111/j.1755-5949.2010.00222x. Go to original source...
    6. McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends Neurosci. 2019;42(3):205-220. doi: 10.1016/j.tins.2018.12.004. Go to original source... Go to PubMed...
    7. Uchida H, Takeudih H, Graff-Guerrero A, et al. Predicting dopamine D2 receptor occupancy from plasma level of anti­psychotic drugs: a systematic rewiev and pooled analysis. J Clin Psychopharmacol. 2011;31(3):318-325. doi : 10.1097/JCP. 0b013e318218d339. Go to original source... Go to PubMed...
    8. Mauri MC, Paletta S, Di Pace C. Clinical pharmacokinetics of atypical antipsychotics: An update. Clin Pharmakinet. 2018;57(12):1493-1528. Go to original source... Go to PubMed...
    9. Hiemke AC, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuro­psychopharmacology: update 2017 Pharmacopsychiatry. 2018;51(1-02):9-62.
    10. Kupu S, Seeman P. Does fast dissotiatin from the dopamine d(2)receptor explain the action of atypical antipsychotic? A new hypotesis. Am J Psychiatry. 2001;158:360-369. Go to original source... Go to PubMed...
    11. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinemia in women: pathophysiology, severity and consequence. Selective literature rewiew. Br J Psychiatry. 2003; 182:199-204. Go to original source... Go to PubMed...
    12. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157(6):975-981. doi: 10.1176/appi.ajp.157.6.975. Go to original source... Go to PubMed...
    13. Wenzel-Seifert K, et al. QTc prolongation by Psychotropic Drugs the Risk of Torsade de Pointes. Deutsches Ärtzteblatt International. 2011;108(41):687-693. Go to original source... Go to PubMed...
    14. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Go to original source... Go to PubMed...
    15. Šilhán, Hýža M, Ambroš S, et al. Terapeutické monitorování psychfarmak: specifické situace . Psychiatrie. 2023;27(3): 133-140.
    16. Patil P, Schwartz TL. Fine Tuning the Use of Second Generation Antipsychotics. J Ment Health Clin Psychol 2018;2(5):22-39. doi.org/10.29245/2578-2959/2018/5.1138. Go to original source...
    17. Češková E, Šilhán P, Kacířová I, et al. Terapeutické monitorování léčiv v psychiatrii. Doporučené postupy psychiatrické péče V. Psychiatrická společnost ČLS JEP 13.9. 2018. [Internet]. Available from: https://postupy-pece.psychiatrie.cz/lecba/monitorovani-lecby-psychofarmaky/terapeuticke-monitorovani-leciv-v-psychiatrii [citováno 2025-24-01].
    18. Krejčí V, Murínová I, Slanař O, Šíma M. Evidence for Therapeutic Drug Monitoring of Atypical Antipsychotics. Prague Medical Report/Vol. 2024;125(2):101-129. doi:10.14712/23362936.2024.10. Go to original source... Go to PubMed...
    19. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25:S12-S21. doi:10.1016/S0924-9338(10)71701-6. Go to original source... Go to PubMed...
    20. Schoretsanitis G, Kane MJ, Correll CJ, et al. Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. The Journal of clinical psychiatry.2020;81(3):1139-1169. doi : 10.4088/JCP.19cs13169. Go to original source... Go to PubMed...
    21. Masopust J, Kopeček M, Protopovová D. Stabilizační a udržovací léčba schizofrenie. Doporučené postupy psychiatrické péče V. Psychiatrická společnost ČLS JEP 24. 3. 2022. [Internet]. Available from: https://postupy-pece.psychiatrie.cz/images/pdf/Stabilizacni-udrzovaci-lecba-schizofrenie-22.pdf [citováno 2024-24-06]. Go to original source...
    22. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guedelines in Psychiatry. 14th ed. West Sussex. UK: Wiley Black­well;2020.
    23. Aichhorn W, Marksteiner J, Walch T, et al. Age and gender effects on olanzapine and risperidone plasma concentrations in childern and adoscents. J Child Adolesc Psychopharmacol. 2007;17(5):665-674. Go to original source... Go to PubMed...
    24. Tašková I. Terapeutické monitorování psychofarmak z pohledu klinického farmaceuta: doporučení versus praxe. Remedia. 2020; 30.
    25. Hart XL, et al. The optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molekular brain imaging and pharmacogenetic test: Focus on antipsychotics. The World Journal of Biological Psychiatry. 25;9:451-536. DOI:10:1080/1562975.2024.2366235. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.